The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer. (I) wherein: R1 is hydrogen, fluoro, cyano, trifluoromethyl, methoxy, or trifluoromethoxy R2 is hydrogen or methyl and R3, R4, R5, R6 and R7 are independently hydrogen, chloro, fluoro, cyano, trifluoromethyl or trifluoromethoxy, provided that at least two of R3, R4, R5, R6 and R7 are hydrogen or a pharmaceutically acceptable salt thereof.La présente invention concerne de nouveaux antagonistes de la voie de la protéine Hedgehog de phtalazine 1,4-disubstituée utiles dans le traitement du cancer.
